Welch & Forbes LLC cut its stake in shares of Eli Lilly And Co (NYSE:LLY) by 2.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 130,769 shares of the company’s stock after selling 2,775 shares during the quarter. Welch & Forbes LLC’s holdings in Eli Lilly And Co were worth $14,624,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently modified their holdings of the business. Larson Financial Group LLC lifted its position in Eli Lilly And Co by 169.4% during the third quarter. Larson Financial Group LLC now owns 1,207 shares of the company’s stock worth $135,000 after acquiring an additional 759 shares during the last quarter. Rockland Trust Co. lifted its position in Eli Lilly And Co by 3.0% during the third quarter. Rockland Trust Co. now owns 45,212 shares of the company’s stock worth $4,851,000 after acquiring an additional 1,307 shares during the last quarter. Affiance Financial LLC acquired a new stake in Eli Lilly And Co during the third quarter worth approximately $201,000. Country Trust Bank lifted its position in Eli Lilly And Co by 20.6% during the third quarter. Country Trust Bank now owns 245,117 shares of the company’s stock worth $27,411,000 after acquiring an additional 41,817 shares during the last quarter. Finally, Juncture Wealth Strategies LLC lifted its position in Eli Lilly And Co by 7.5% during the third quarter. Juncture Wealth Strategies LLC now owns 4,300 shares of the company’s stock worth $481,000 after acquiring an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 76.72% of the company’s stock.
Several equities research analysts have issued reports on the stock. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Bank of America set a $120.00 price objective on shares of Eli Lilly And Co and gave the stock a “neutral” rating in a research report on Tuesday, September 10th. Nine analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Eli Lilly And Co currently has a consensus rating of “Hold” and an average price target of $122.92.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The company had revenue of $5.64 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm earned $1.48 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. Analysts forecast that Eli Lilly And Co will post 5.73 earnings per share for the current fiscal year.
In related news, SVP Alfonso G. Zulueta sold 19,500 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now directly owns 38,306 shares of the company’s stock, valued at $4,325,130.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Stephen F. Fry sold 9,452 shares of Eli Lilly And Co stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the completion of the transaction, the senior vice president now directly owns 100,211 shares in the company, valued at $11,524,265. The disclosure for this sale can be found here. Insiders have sold 243,452 shares of company stock worth $28,252,925 over the last ninety days. Insiders own 0.11% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Momentum Indicator: Relative Strength Index
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.